Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The French pharmacovigilance system: structure and missions].

M Welsch1, M Alt, M H Richard

  • 1Centre régional de Pharmacovigilance Alsace, Hôpitaux Universitaires de Strasbourg.

Presse Medicale (Paris, France : 1983)
|February 22, 2000
PubMed
Summary

France

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Search for a τ^{+}τ^{-} Resonance in e^{+}e^{-}→μ^{+}μ^{-}τ^{+}τ^{-} Events with the Belle II Experiment.

Physical review letters·2023
Same author

Measurement of CP Violation in B^{0}→K_{S}^{0}π^{0} Decays at Belle II.

Physical review letters·2023
Same author

Test of Light-Lepton Universality in the Rates of Inclusive Semileptonic B-Meson Decays at Belle II.

Physical review letters·2023
Same author

Search for an Invisible Z^{'} in a Final State with Two Muons and Missing Energy at Belle II.

Physical review letters·2023
Same author

Search for Lepton-Flavor-Violating τ Decays to a Lepton and an Invisible Boson at Belle II.

Physical review letters·2023
Same author

Observation of e^{+}e^{-}→ωχ_{bJ}(1P) and Search for X_{b}→ωϒ(1S) at sqrt[s] near 10.75 GeV.

Physical review letters·2023

Area of Science:

  • Pharmacovigilance and Pharmacoepidemiology
  • Drug Safety and Adverse Event Monitoring
  • Public Health and Regulatory Science

Background:

  • The French pharmacovigilance system utilizes a decentralized network of 31 regional centers.
  • Effective pharmacovigilance relies on robust causality assessment methods.
  • Pharmacoepidemiology enhances the evaluation of drug-related adverse effects.

Purpose of the Study:

  • To describe the structure and function of the French pharmacovigilance system.
  • To outline the compulsory causality assessment methods employed.
  • To highlight the role of the National Commission of Pharmacovigilance in drug safety.

Main Methods:

  • Network of 31 regional pharmacovigilance centers.
  • Compulsory causality assessment for adverse drug reactions.
  • Application of pharmacoepidemiology for enhanced evaluation.
  • Centralized data assessment by the National Commission of Pharmacovigilance at AFSSAPS.

Main Results:

  • A comprehensive network ensures proximity to healthcare professionals.
  • Standardized causality assessment ensures rigorous evaluation of drug-adverse effect relationships.
  • Pharmacoepidemiology provides additional data for robust assessment.
  • AFSSAPS centralizes data for informed decision-making.

Conclusions:

  • The French pharmacovigilance system integrates a network, standardized assessment, and pharmacoepidemiology for drug safety.
  • The National Commission provides expert advice to authorities for preventing adverse drug effects.
  • This system aims to minimize drug-related harm through continuous monitoring and evaluation.

Related Experiment Videos